On October 29, 2018 MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR) reported that it will publish its third quarter 2018 results on November 5, 2018 at 10:00pm CET (9:00pm GMT; 4:00pm EST) (Press release, MorphoSys, OCT 29, 2018, View Source [SID1234530315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Management team of MorphoSys AG will host a conference call and webcast on November 6, 2018 at 2:00pm CET (1:00pm GMT; 8:00am EST) to present MorphoSys’s third quarter results 2018 and provide further details on the Company’s latest developments.

Date of the conference call: Tuesday, November 6, 2018
Time: 2:00pm CET (1:00pm GMT, 8:00am EST)
Dial-in numbers (listen only)
Germany: +49 (0) 69 201 744 210
United Kingdom: +44 (0) 203 009 2470
USA: +1 (0) 877 423 0830
Participant PIN: 79499880#

Company participants in the call will be:

Dr. Simon Moroney, Chief Executive Officer

Jens Holstein, Chief Financial Officer

Participants are kindly requested to dial in up to 10 minutes before the call to ensure a secure line and a prompt start. If they need assistance during the conference call, participants are kindly requested to press * and 0 on their telephone to get connected with an operator.

The presentation slides and webcast link will be available at the Company’s website at View Source

A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event

On October 29, 2018 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the "notes") pursuant to the exercise in full of the option to purchase additional notes granted to the initial purchasers in Karyopharm’s previously announced private offering of $150 million aggregate principal amount of notes to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act") (Press release, Karyopharm, OCT 29, 2018, View Source [SID1234530309]). The additional notes were sold on the same terms in all respects as the notes previously issued on October 16, 2018, and the terms of the additional notes are identical to those previously issued. The closing of the sale of the additional notes occurred on October 26, 2018. Following such closing, Karyopharm has issued a total of $172.5 million aggregate principal amount of notes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The notes were offered and sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The offer and sale of the notes and the shares of common stock issuable upon conversion of the notes, if any, have not been and will not be registered under the Securities Act or the securities laws of any other jurisdiction, and the notes and any such shares may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. Any offer of the notes was made only by means of a private offering memorandum.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the notes or any other securities, nor shall there be any offer, solicitation or sale of the notes or any other securities (including the shares of Karyopharm’s common stock issuable upon conversion of the notes, if any) in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

On October 29, 2018 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that Dan Shine, senior vice president and president, Analytical Instruments, will present at the Baird 2018 Global Industrial Conference on Wednesday, November 7, 2018, at 12:30 p.m. (CST) at the Four Seasons Hotel, Chicago, Ill (Press release, Thermo Fisher Scientific, OCT 29, 2018, View Source [SID1234530300]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

You can access the live webcast of the presentation in the Investors section of our website, www.thermofisher.com.

On October 29, 2018 Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that the Company will host a conference call and live audio webcast on Thursday, November 1, 2018 at 5:00 p.m. ET to report its third quarter 2018 financial results and provide a corporate update (Press release, Fate Therapeutics, OCT 29, 2018, http://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-webcast-conference-call-reporting-third-4 [SID1234530298]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 6998539. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event

On October 29, 2018 TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, reported the achievement of development milestones that trigger an $18 million payment from Janssen Biotech Inc. (Janssen) (Press release, TESARO, OCT 29, 2018, View Source [SID1234530297]). The milestones are related to Janssen’s ongoing GALAHAD trial, which is assessing niraparib monotherapy for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair anomalies. Data from the trial are anticipated to support global regulatory filings in 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, data from the Phase 1b BEDIVERE trial were recently presented at the European Society of Clinical Oncology (ESMO) (Free ESMO Whitepaper) and demonstrated the safety and tolerability of combining niraparib with abiraterone acetate + prednisone (AA-P) in men with mCRPC. Data from the BEDIVERE trial will be used to inform the dosing regimen in a future Phase 3 trial that will assess the clinical benefit of niraparib in combination with AA-P in mCRPC patients.

TESARO entered into a global prostate collaboration and license agreement with Janssen in 2016, through which Janssen received rights to develop and commercialize niraparib for patients with prostate cancer worldwide, except Japan. Under the terms of the agreement, TESARO is eligible to receive development, regulatory and commercial milestones, in addition to royalty payments.

About the Janssen GALAHAD Clinical Trial
GALAHAD is an ongoing Phase 2, open-label, single arm trial designed to evaluate the safety and efficacy of niraparib monotherapy (300mg daily) in men with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair anomalies progressing on/after taxane-based chemotherapy and androgen receptor targeted therapy. Patients are enrolled in the study based on their DNA-repair deficiency status.

About the Janssen BEDIVERE Clinical Trial
BEDIVERE is an ongoing Phase 1b, open-label, dose-selection study with dose expansion designed to evaluate the safety of niraparib in combination with AA-P in men with metastatic castration-resistant prostate cancer (mCRPC) who may or may not have had DNA-repair anomalies.

About ZEJULA (Niraparib)
Niraparib is marketed in the United States and Europe under trade name ZEJULA. ZEJULA (niraparib) is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. In preclinical studies, ZEJULA concentrates in the tumor relative to plasma, delivering greater than 90% durable inhibition of PARP 1/2 and a persistent antitumor effect.